Faeth Therapeutics rises after FDA grants fast-track status for cancer drug
FTH•Treatment details and study timeline
PIKTOR combines the oral drugs sapanisertib and serabelisib, which are designed to block cancer-growth signals, and is being tested in patients whose cancer has worsened after prior chemotherapy and immunotherapy.
The company expects results from an ongoing mid-stage study by year-end 2026.
As of last close, FTH was up 203.1% year to date.
FDA fast-track designation for PIKTOR
Shares of cancer-drug developer Faeth Therapeutics FTH.O rose 2% to $33 premarket after the company said the U.S. FDA has granted fast-track status to its experimental two-drug treatment PIKTOR, in combination with chemotherapy, for certain patients with advanced or recurring endometrial cancer, a type of cancer that starts in the inner lining of the uterus.
The FDA's fast-track tag is meant to speed up the development and review of treatments for serious diseases with unmet medical needs.
